September 15, 2025
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) announces today that it intends to extend the settlement of two forward contracts for 2 million long-term incentive plans shares each as part of the share repurchase program earlier announced on June 14, 2023. The planned extension will postpone the original maturity dates in Q4 2025 by one year to a new maturity date in Q4 2026. Further details will be available via this link.
For further information, please contact:
Michael Fuchs
Philips Global External Relations
Tel.: +31 6 1486 9261
E-mail: michael.fuchs@philips.com
Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
-
展望 “健康中国2030” ,Eurofins Central Lab助力临床试验出海,加速中国生物医药全球化苏州2025年9月15日 美通社 -- 2025年苏州OCT会议近日圆满落幕,本次会议聚焦中国生物医药行业的迅猛发展与全球化进程。多位行业领袖、政策专家与企业代表齐聚一堂,共2025-09-15
-
韩国演员李恩知与携手bnt拍摄写真 回顾成长历程畅谈未来目标近日,“Mano Family”代表——恩知姐姐(本名李恩知)与韩国bnt娱乐携手完成了一组全新写真拍摄。活跃于中韩两地的她,一直致力于搭建两国网红交流的桥梁。此次,她罕见2025-09-15
-
大睿生物宣布RN3161澳洲临床试验申请获受理差异化INHBE siRNA进入临床,开启肥胖治疗新格局 上海和加利福尼亚州圣巴巴拉2025年9月15日 美通社 -- 专注于开发下一代RNAi疗法的全球化生物医药公司大睿生物(Rona2025-09-15
-
FutureCeuticals对NeuroRush所有者因 涉嫌山寨原料侵犯专利提起诉讼伊利诺伊州莫门斯2025年9月15日 美通社 -- VDF FutureCeuticals, Inc.对Aura Scientific提起诉讼,声称其大脑性能成分NeuroRush(一种整咖啡果提取物)侵犯了FutureCeut2025-09-15
-
法天使与零一万物发布法务智能体平台,让AI成为法务部的超级员工近日,法天使携手零一万物在京举办「法务智能体平台」发布会,正式对外发布法务智能体平台。在会上,法天使与零一万物带来了为企业法务部门打造的智能体平台解决方案,这2025-09-15